Citations

Clear

2429 citation(s) found for "Shah, SS".

GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes
Makwana, Bhargav , Patel, Manav, Panchal, Krisha , Shah, Jui , Kumar, Ashish , Patel, Tirth, Kosiborod, Mikhail, Ramsey, Kathryn Moynihan , Nohria, Anju, Butler, Javed , Ganatra, Sarju , Ramsey, David J. , Dani, Sourbha S. , Khadke, Sumanth , Kosiborod, Mikhail , Fonarow, Gregg C. , Nohria, Anju

Mayo Clinic

JAMA Network Open | August 11, 2025 | Volume: 8 | Issue: 8 | Pages: e2526321

10.1001/jamanetworkopen.2025.26321 | PMID 40788647 Get It

Importance Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with increased risk of diabetic retinopathy (DR) and nonarteritic anterior ischemic optic neuropathy (NAION). The risk of sight-threatening complications associated with GLP-1 RAs is underexamined. Objective To investigate whether the use of GLP-1 RAs in patients with T2D is associated with the development of DR, NAION, or DR complications. Design, Setting, and Participants This retrospective cohort study of adults (aged ≥18 years) with T2D and a recent hemoglobin A 1c level of 6.5% or higher was conducted between January 1, 2015, and September 30, 2022, using the TriNetX database. The cohort was divided into 2 groups, adjusted for baseline characteristics through propensity score matching (PSM), based on whether the individuals received prescriptions for a GLP-1 RA. The statistical analysis was conducted on October 10, 2024. Exposures At least 2 prescriptions of a GLP-1 RA given 6 months apart. Main Outcomes and Measures Cox proportional hazard regression models were used to evaluate the primary outcome: association between GLP-1 RAs and the risk of incident DR, NAION, or sight-threatening complications over a 2-year follow-up period. Results After PSM, 185 066 individuals (mean [SD] age, 59.0 [12.5] years; 93 389 females [50.5%]) were prescribed GLP-1 receptor agonists. Use of GLP-1 RAs was associated with an increased incidence of DR (hazard ratio [HR], 1.07; 95% CI, 1.03-1.11), while no statistically significant difference was observed in the risk of NAION (HR, 1.26; 95% CI, 0.94-1.70). In a subgroup analysis of 32 695 patients with preexisting DR, GLP-1 RAs were not associated with progression to proliferative DR (HR, 1.06; 95% CI, 0.97-1.15) or diabetic macular edema (HR, 0.98; 95% CI, 0.95-1.01) but were associated with a lower occurrence of vitreous hemorrhages (HR, 0.74; 95% CI, 0.68-0.80), neovascular glaucoma (HR, 0.78; 95% CI, 0.68-0.88), or blindness (HR, 0.77; 95% CI, 0.73-0.82). Conclusions and Relevance In this cohort study of individuals with T2D, GLP-1 RA use was associated with a modestly increased risk of incident DR; however, fewer patients experienced sight-threatening DR complications, including blindness, even among those with preexisting DR. These findings suggest that all patients with T2D treated with GLP-1 RAs, regardless of preexisting DR, should be regularly screened and monitored for potential complications of T2D.
Recent Progress in the Field of Artificial Organs
Ursoleo, Jacopo D’Andria , Woolley, Brian E. , Curran, Brett F., Doran‐Gallastegi, Ander, Treffalls, John A. , D'Andria Ursoleo, Jacopo , Shah, Aakash

Mayo Clinic

Artificial Organs | August 7, 2025 | Volume: 49 | Issue: 10 | Pages: 1483-1485

10.1111/aor.70002 | PMID 40772601 Get It

SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome
Gajjar, Aryan , Raju, Arvind Kumar Venkataramana , Gajjar, Amar , Menon, Mythili, Shah, Syed Asfand Yar , Weinberg, Andrew M., Raju, Arvind Kumar , Gajjar, Amani, Dani, Sourbha S.

Mayo Clinic

Biomedicines | August 7, 2025 | Volume: 13 | Issue: 8 | Pages: 1924

10.3390/biomedicines13081924 | PMID 40868177 Get It

Cardiovascular–Kidney–Metabolic (CKM) syndrome symbolizes a single pathophysiologic entity including obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. These conditions altogether accelerate adverse outcomes when they coexist. Recent evidence has shown that the function of glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium–glucose cotransporter-2 inhibitors (SGLT2i) alleviate stress on multiple organs. SGLT2i has been demonstrated to benefit heart failure, hemodynamic regulation, and renal protection while GLP-1RA on the other hand has been shown to demonstrate a strong impact on glycemic management, weight loss, and atherosclerotic cardiovascular disease. This review will aim to understand and evaluate the mechanistic rationalization, clinical evidence, and the potential therapeutic treatment of SGLT2 inhibitors and GLP-1 receptor agonists to treat individuals who have CKM syndrome. This analysis also assesses whether combination therapy can be a synergistic approach that may benefit patients but is still underutilized because of the lack of clear guidelines, the associated costs, and disparities in accessibility. Therefore, in this review, we will be discussing the combination therapy’s additive and synergistic effects, current recommendations and clinical evidence, and mechanistic insights of these GLT2 inhibitors and GLP-1 receptor agonists in CKM syndrome patients. Overall, early and combination usage of GLP-1RA and SGLT2i may be essential to demonstrating a significant shift in modern cardiometabolic therapy toward patient-centered care.
Interobserver Reproducibility of Pelvicalyceal Invasion in Renal Cell Carcinoma Nephrectomies Among Genitourinary Pathologists
Sangoi, Ankur R. , Mubeen, Aysha , Humble, Robert , Wu, Douglas, Amin, Mahul, Aron, Manju , Brimo, Fadi , Chan, Emily , Cheng, Liang, Cheville, John C. , Collins, Katrina, Cornejo, Kristine M. , Downes, Michelle R. , Epstein, Jonathan I. , Hirsch, Michelle S. , Mohanty, Sambit K. , Netto, George J. , Osunkoya, Adeboye O. , Paner, Gladell P. , Rao, Priya, Smith, Steven C. , Tickoo, Satish K. , Tretiakova, Maria , Trpkov, Kiril , Wobker, Sara E. , Tamboli, Pheroze, Zynger, Debra L. , Cheng, Liang , Collins, Katrina , Cheng, Liang , Sangoi, Ankur R , Tretiakova, Maria S , Trpkov, Kiril , Akgül, Mahmut , Pacheco, Richard R. , Acosta, Andrés , Amin, Mahul, Dhillon, Jasreman , Kapur, Payal , Lobo, Anandi , Mehra, Rohit, Saleeb, Rola , Shah, Rajal B. , Shen, Steven S. , Tamboli, Pheroze, Williamson, Sean R.

Mayo Clinic

American Journal of Surgical Pathology | July 30, 2025 | Volume: 49 | Issue: 12 | Pages: 1307-1314

10.1097/pas.0000000000002456 | PMID 40734292 Get It

Pelvicalyceal invasion (PCI) is a relatively novel pT3a staging parameter for renal cell carcinoma (RCC) nephrectomies. While interobserver reproducibility staging studies of sinus/vascular invasion in RCC exist, a similar evaluation for PCI has not been performed. Moreover, in our experience, there is also diagnostic variability in how pathologists interpret PCI. Herein, we explore interobserver reproducibility among genitourinary (GU) pathologists. Twenty hematoxylin and eosin-stained digitized slides from RCCs (all grossly approaching the renal pelvis) were distributed to 31 GU pathologists to classify each as PCI or not PCI based on their respective clinical practices; slides with concomitant sinus/fat/vascular invasion were excluded. Slides were then evaluated for the following 4 morphologic features: tumor abutting renal pelvis, tumor pushing/indenting into the renal pelvis, polypoid configuration of tumor into the renal pelvis, and tumor eroding through renal pelvic urothelium. Interobserver reproducibility was assessed, and the morphologic features were correlated with PCI. Relationships between pathologists’ interpretations, morphologic features, and PCI were evaluated using hierarchical clustering. Although the diagnosis of PCI was relatively uniform with a majority agreement (>67%) reached in 16/20 slides, overall interobserver reproducibility was only moderate (kappa=0.601). While all 4 morphologic features were sensitive for PCI, polypoid configuration of the tumor into the renal pelvis and the tumor eroding through the renal pelvic urothelium were most specific (90%, 100%, respectively). Although we show general consensus among genitourinary pathologists on PCI assessment, clarifying the diagnostic guidelines with specific criteria should be included in pathologic staging systems.
Outcomes of Post‐Transplant Rh‐ GCSF and Decitabine Maintenance Therapy in Patients With High‐Risk Myeloid Neoplasm
Palmer, Mathias , Baranwal, Anmol , Basmaci, Rami, Hassan, Khalil , Kutzke, Jade L. , Bartoo, Gabriel , Murthy, Hemant S. , Foran, James M. , Mangaonkar, Abhishek A. , Hefazi, Mehrdad , Matin, Aasiya , Litzow, Mark R. , Alkhateeb, Hassan B. , Murthy, Hemant S , Litzow, Mark R. , Shah, Mithun V , Hefazi, Mehrdad , Alkhateeb, Hassan B , Baranwal, Anmol , Hogan, William J. , Shah, Meera

Mayo Clinic

American Journal of Hematology | July 29, 2025 | Volume: 100 | Issue: 10 | Pages: 1891-1894

10.1002/ajh.70018 | PMID 40728375 Get It

Molecular, histologic, and clinical characterization of methylation class pleomorphic xanthoastrocytoma: An analysis of 469 tumors
Dampier, Christopher H. , Shah, Niharika, Neto, Osório Lopes Abath , Abdullaev, Zied , Alexandrescu, Sanda , Armstrong, Terri, Baker, Tiffany , Cathcart, Sahara , Chung, Hye‐Jung, Cimino, Patrick J. , Conway, Kyle , Dazelle, Karen , Etminam, Nima, Fernandes, Igor, Ferrone, Christina K. , Gilani, Ahmed , Gilbert, Mark, Gregory, Jason V. , Lee, Han Sung, Lopes, Maria Beatriz, Neill, Stewart G. , Ozer, Byram H. , Paulus, Werner, Penas‐Prado, Marta, Prinz, Marco , Pytel, Peter , Quezado, Martha , Raffeld, Mark , Rajan, Sharika, Reifenberger, Guido, Robinson, Lorraina , Schittenhelm, Jens , Thomas-Ogunniyi, Jaiyeola , Toland, Angus , Turakulov, Rust , Aldape, Kenneth , Cimino, Patrick J , Mao, Qinwen , Prinz, Marco , Ratliff, Miriam , Robinson, Lorraina , Schittenhelm, Jens , Thomas, Christian , Vaubel, Rachael A , Wu, Jing , Giannini, Caterina , Brandner, Sebastian , von Deimling, Andreas , Aldape, Kenneth , Dampier, Christopher H , Galbraith, Kristyn , Ebrahimi, Azadeh , Andreiuolo, Felipe , Cotter, Jennifer A. , Costa, Felipe D’Almeida , Ferman, Sima , Fernandes, Igor, Gregory, Jason, Ketchum, Courtney , Lee, Ina , Lopes, M. Beatriz S. , Mao, Qinwen , Marshall, Michael S. , McCord, Matthew , Nirschl, Jeffrey , Peñas-Prado, Marta , Schrimpf, Daniel , Singh, Omkar , Thomas, Christian , Thomas, Diana , Vaubel, Rachael A. , Wadhwani, Nitin R. , Giannini, Caterina , Snuderl, Matija , Deimling, Andreas von

Mayo Clinic

Neuro-Oncology Advances | July 21, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdaf089 | PMID 40735274 Get It

Abstract Background Methylation class pleomorphic xanthoastrocytoma (mcPXA) comprises tumors with the DNA methylation signature of classical PXA but with a wider histologic spectrum, including overlap with glioblastoma (GBM). Methods To clarify the histologic and molecular scope of mcPXA and characterize its clinical behavior, a cohort of 469 tumor samples from 458 patients matching to mcPXA by the DKFZ classifier (v12.6 score ≥0.85) was interrogated. Results Patient median age was 23 years (range 1-73 years) with a female predominance (259 female/199 male). CDKN2A/B homozygous deletion was observed in 406 of 469 (87%) samples. In samples tested for BRAF p.V600E mutations (n = 279), 240 (86%) harbored the mutation. A chr7+/chr10− pattern was observed in 103 of 469 (22%) samples. Among samples tested for TERT promoter mutations (n = 143), 32 (22%) harbored the mutation. Progression-free and overall survival of patients with mcPXA were comparable to patients with methylation class IDH-mutant astrocytoma, low grade, but a GBM-like subset (ie, cases with a pre-methylation working diagnosis of GBM) showed shorter survival. Histologic features of high grade, including palisading necrosis and microvascular proliferation, were prognostic in mcPXA. Compared to patients with BRAF p.V600E-altered GBM, patients with mcPXA were younger and had a lower frequency of TERT promoter mutations. Conclusion Tumors in mcPXA share molecular characteristics with histologically defined PXA, and high-grade histologic features can help predict their clinical behavior. The use of an epigenetic classification of PXA reveals that this group of tumors is more common than previously appreciated and warrants in-depth study to identify efficacious therapeutic options.
Neurotoxicants driving glial aging: role of astrocytic aging in non-cell autonomous neurodegeneration
González, P. , Langley, Monica R. , Plunk, Elizabeth , Strazdins, Rachel, Abu-Salah, Abdulla , Anchan, Aiesha , Sarkar, Souvarish , Langley, Monica, Sarkar, Souvarish , Reina-Gonzalez, Pablo, Ay, Muhammet , Shah, Ahmed

Mayo Clinic

Toxicological Sciences | July 18, 2025 | Volume: 207 | Issue: 1 | Pages: 20-28

10.1093/toxsci/kfaf088 | PMID 40680177 Get It

Abstract Astrocytes, the most abundant glial cells in the central nervous system (CNS), play essential roles in maintaining neuronal homeostasis, synaptic regulation, and blood–brain barrier integrity. However, these cells can undergo senescence—a cellular state characterized by irreversible growth arrest and the secretion of proinflammatory factors—in response to aging and pathological stressors, contributing to synaptic dysfunction and neurodegenerative diseases. This review examines the molecular mechanisms driving astrocytic senescence, including oxidative stress, DNA damage, and inflammatory signaling pathways such as NF-κB and the senescence-associated secretory phenotype. A particular focus is placed on the diverse array of known chemical inducers of astrocyte senescence, such as pesticides and heavy metals, which provide critical insights into the processes governing cellular aging in the brain. By analyzing the effects of these inducers, we highlight their implications for neurodegenerative disease progression and brain aging. Understanding astrocytic senescence offers new insights into age-related neuropathology and presents promising avenues for targeted therapies in neurodegenerative disorders induced by environmental toxicants.
Health Disparities and Impact of Social Vulnerability on Diagnosis and Outcomes in Vestibular Disorders
Nassar, Sami I. , Young, Benjamin D., Shah, Sunny , Pitiranggon, Chada , Platt, Ladd M., Young, Benjamin D., Staab, Jeffrey P. , Platt, Ladd M., Nguyen, Shaun A. , Rizk, Habib G.

Mayo Clinic

Ear & Hearing | July 15, 2025 | Volume: 46 | Issue: 5 | Pages: 1254-1265

10.1097/aud.0000000000001665 | PMID 40660454 Get It

Objectives: Examining the effect of demographics and social vulnerability on diagnosis and management of patients with vestibular and balance disorders. Design: Retrospective review of a database of patients presenting with vestibular symptoms to a multidisciplinary tertiary vestibular clinic between January and October 2021. Main outcomes included odds ratios of final diagnosis, treatment response, time to presentation by demographic variable, insurance status, residence, and social vulnerability factors according to the 2018 Centers for Disease Control Social Vulnerability Index. Results: Five hundred thirty-six patients with definitive vestibular diagnoses and treatment outcome data were included. Mean age at presentation was 60.4 ± 16.5 years. Women (n = 389, 72.6%) outnumbered men (n = 147, 27.4%). Most patients self-identified as White (n = 440, 82.1%) and non-Hispanic (n = 521, 97.2%). Overall, 17.4% of participants belonged to a minority group. Socioeconomic status, household composition, geographic location, and insurance status were associated with patient diagnoses received. Patients from the lowest socioeconomic class were more likely to be diagnosed with Meniere’s disease. In addition, patients with private insurance were more likely to be diagnosed with Meniere disease or vestibular migraine than those with Medicare insurance. Geographic distance greater than 60 miles from the clinic was associated with a higher likelihood to present >90 days since initial symptom onset. Housing and transportation vulnerabilities were associated with decreased treatment response. Conclusions: Diagnostic classification, time to presentation, and treatment outcomes differed according to demographic and social vulnerability factors. There was no single unifying theme among vulnerabilities, but the results of this study offer preliminary data to design future investigations on regional and national levels to understand and mitigate the effects of social vulnerability factors on access to specialty vestibular care and outcomes of treatment.
Multicenter evaluation of blood culture contamination and blood cultures practices in US acute care hospitals: time for standardization
Fabre, Valeria , Hsu, Yea‐Jen , Carroll, Karen C. , Salinas, Alejandra , Abbo, Lilian M. , Bower, Chris , Berry, J. Michael, Degnan, Kathleen, Dhaubhadel, Pragya, Dress, Marci, Feeser, Baevin , Fisher, Mark , Flynn, Cynthia E. , Gettler, Erin , Glasser, Laurel J., Johnson, J. Kristie, Karaba, Sara M. , Kubischta, Alyssa, Landrum, B. Mark, Martinez, Marvin, Mermel, Leonard A. , Pepe, Dana , Qasba, Sonia, Rittmann, Barry , Robinson, Evan D. , Rosa, Rossana , Salinas, Jorge , Shah, Aditya , Schrank, Gregory M. , Spivak, Emily S , Stewart, Kathleen O., Wasylyshyn, Anastasia , Virk, Zunaira, Cosgrove, Sara E. , Abbo, Lilian M , Karaba, Sara M , Fabre, Valeria , Milstone, Aaron M. , Berry, Jennifer, Boyd, Sarah, Diekema, Daniel J. , Ford, Bradley , Glasser, Laurel J., Howard‐Anderson, Jessica , Kim, Justin , Mathers, Amy J. , Moehring, Rebekah W. , O’Horo, John C. , Rodriguez‐Nava, Guillermo , Ryder, Jonathan H. , Shelly, Mark , Talbot, Thomas R. , Schooneveld, Trevor Van , Gadala, Avinash

Mayo Clinic

Journal of Clinical Microbiology | July 11, 2025 | Volume: 63 | Issue: 8 | Pages: No page available

10.1128/jcm.00530-25 | PMID 40643261 Get It

ABSTRACT Clinical and Laboratory Standards Institute (CLSI) recommends a blood culture contamination (BCC) threshold of <3%, with ≤1% considered optimal. However, there is not a standardized definition of BCC, and the effect of multiple definitions on BCC rates or what definitions laboratories use remain unknown. We surveyed 52 hospitals and analyzed 362,078 blood cultures (BCx) collected 1 September 2019 to 31 August 2021 from 62 intensive care units (ICUs) and 231 wards from 48 of these hospitals. We calculated and compared BCC rates using the College of American Pathologists (CAP) or CLSI criteria (both utilize a limited number of skin commensals to define BCC) and the comprehensive National Healthcare Safety Network (NHSN) commensal list. We characterized factors associated with BCC and related outcomes (central-line associated bloodstream infection [CLABSI] and vancomycin use). BCC, BCx positivity, and single BCx rates were monitored by 100%, 39%, and 21% of hospitals, respectively. Hospitals used CAP (65%), CLSI (17%), and NHSN (17%) criteria to define BCC. Mean BCC rate by CAP (CAP-BCC) was 1.38% for ICUs and 0.96% for wards. BCC rates remained similar by CLSI criteria but increased when using NHSN list. Sharing BCC data outside of the laboratory, measuring additional BCx quality indicators, and limiting central catheter-drawn BCx were associated with lower BCC rates. BCC was associated with higher CLABSI rates in ICUs. This study demonstrated variability in laboratory practices and opportunities to optimize BCx stewardship. IMPORTANCE Blood culture contamination (BCC) is associated with patient harm and unnecessary use of healthcare resources. BCC thresholds have been established; however, multiple BCC definitions exist. There is limited data on how BCC rates differ depending on the BCC definition used, what definitions laboratories most commonly use, or their approach to other blood cultures (BCx) quality indicators such as single rates or BCx positivity. A cross-sectional multicenter survey and analysis of BCx data from intensive care unit and wards revealed that most laboratories did not track single BCx or BCx positivity rates and that there was variability in how BCC was defined. Additionally, BCC rates were influenced by the definition used. BCC was associated with increased central-line associated bloodstream infection rates.